Atorvastatin reduces arterial stiffness in patients with rheumatoid arthritis

Background: Chronic systemic inflammation may contribute to accelerated atherosclerosis and increased arterial stiffness in patients with rheumatoid arthritis (RA). In addition to lowering cholesterol, statins have immunomodulatory effects which may be especially beneficial in patients with RA who have systemic immune activation. Objective: To investigate the effect of atorvastatin on the augmentation index (Alx: a measure of arterial stiffness) and systemic inflammation in RA. Methods: 29 patients with RA (mean (SD) age 55 (13) years) with moderately active disease of long duration were studied. Alx, lipid levels, serum inflammatory markers, and disease activity score were measured before and after 12 weeks of atorvastatin 20 mg daily. Results: Alx improved significantly from 34.1 (11.6)% to 29.9 (11)% (p=0.0002), with the greatest improvements in Alx occurring in those subjects with the highest disease activity scores (r=-0.5, p=0.007). Total and LDL cholesterol were reduced from 5.5 (0.9) to 3.9 (0.7) mmol/I and 3.3 (0.8) to 1.9 (0.6) mmol/I, respectively (p=0.0001). Serum inflammatory markers remained unchanged during the study. Conclusions: Atorvastatin significantly reduced arterial stiffness in patients with RA. The greatest improvements were seen in patients with more active disease, suggesting that, in addition to the beneficial effects of cholesterol reduction, immune modulation may contribute to the cardioprotective effect of statins